Langerhans cell histiocytosis with <i>BRAF</i> p.N486_P490del or <i>MAP2K1</i> p.K57_G61del treated by the MEK inhibitor trametinib

Yoav H. Messinger(Children’s Minnesota - St. Paul Hospital), Michael K. Richards(Minnesota West Community & Technical College), Bruce Bostrom(Minnesota West Community & Technical College), Lane H. Miller(Center for Cancer and Blood Disorders), Nathan Gossai(University of Minnesota Children's Hospital), Damon R. Olson(Children's Minnesota)
Pediatric Blood & Cancer
September 29, 2020
10.1002/pbc.28712
Cited by 20

Related Papers

A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
|Blood|2002|496
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group
|Blood|2003|361
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia
|New England Journal of Medicine|1987|334
The genomic landscape of juvenile myelomonocytic leukemia
|Nature Genetics|2015|310
Juvenile xanthogranuloma: Forms of systemic disease and their clinical implications
|The Journal of Pediatrics|1996|294